Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0019693 (HIV)
 170,526 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Although a recent Cavalieri d'Oro et al. article correctly concludes that while barrier methods reduce the risk of gonorrhea and HIV, they may be less consistent for other diseases, the review does not include the female condom, the newest method of barrier contraception. Laboratory tests have shown polyurethane, the material of which the new condom is manufactured, to be impermeable to HIV and cytomegalovirus. Similar permeability studies using bacteriophages smaller than hepatitis and HIV show the membrane to be a complete barrier. As such, one may expect polyurethane to be the raw material from which male condoms will be made in the future. One clinical study assessed the prevention of reinfection with Trichomonas vaginalis among 104 women who had sexual intercourse with infected male partners. No woman who used the female condom during every act of sexual intercourse became infected. 14% of nonusers and 14% of inconsistent users were, however, reinfected. A study by Soper et al. found use of the female condom to not be associated with genital trauma. Leeper and Conrardy subjected the female condom and the male condom to the standard ASTM water leak test to find a 0.6% incidence of leakage from pinholes and tears for the female condom compared to 3.5% with the male condom. The risk of semen leakage during actual use as identified by acid phosphatase was 2.7% with the female condom and 8.1% with the male condom. Perfect users of the female condom may expect a 2.6% probability of failure over six months' use. Perfect use, however, reduces the annual risk of acquiring HIV by more than 90% among women who have sexual intercourse twice weekly with an infected male.
 ...
PMID:Barrier methods of contraception. 770 60

Placental macrophages were isolated and cultured in vitro to investigate their susceptibility to HIV infection and possible role in vertical transmission of HIV. After 10 days of in vitro culture the cells were positive for nonspecific esterase and acid phosphatase and negative for myeloperoxidase and placental alkaline phosphatase. They expressed cell surface HLA-ABC, HLA-DR, CD45, as well as CD68 intracellularly, as detected by flow cytometry, confirming their macrophage lineage. Approximately 80% of cells expressed surface CD14. CD4 antigen was expressed at very low levels and was confirmed by antibody blocking experiments. Infection of placental macrophage cultures with HIV resulted in a transient peak of viral replication 3 to 7 days after infection, but no later rise in HIV was detected with culture of up to 60 days. HIV replication was not up-regulated by coculture with phytohemagglutinin-stimulated lymphocytes or by treating infected cultures with tumor necrosis factor alpha or granulocyte-macrophage colony-stimulating factor.
 ...
PMID:HIV infection of placental macrophages: their potential role in vertical transmission. 808 96

The RAW264 murine macrophage cell line was used as a model to examine the role of the tat and nef gene products in the transcription regulation of the human immunodeficiency virus type 1 (HIV-1) long terminal repeat (LTR) in macrophages. Contrary to claims that the activity of the HIV-1 LTR responds poorly in rodent cells to trans activation by the viral tat gene product, cotransfection of RAW264 cells with a tat expression plasmid in transient transfection assays caused a > 20-fold increase in reporter gene expression that was inhibited by mutations in the TAR region. RAW264 cells stably transfected with the tat plasmid displayed similarly elevated HIV-1 LTR-driven reporter gene activity. By contrast to previous reports indicating a negative role for nef in HIV transcription, cotransfection of RAW264 cells with a nef expression plasmid trans activated the HIV-1 LTR driving either a chloramphenicol acetyltransferase or a luciferase reporter gene. The action of nef was specific to the LTR, as expression of nef had no effect on the activity of the simian virus 40, c-fms, urokinase plasminogen activator, or type 5 acid phosphatase promoter. trans-activating activity was also manifested by a frameshift mutant expressing only the first 35 amino acids of the protein. The effects of nef were multiplicative with those of tat gene product and occurred even in the presence of bacterial lipopolysaccharide, which itself activated LTR-directed transcription. Examination of the effects of selected mutations in the LTR revealed that neither the kappa B sites in the direct repeat enhancer nor the TAR region was required as a cis-acting element in nef action. The action of nef was not species restricted; it was able to trans activate in the human monocyte-like cell line Mono Mac 6. The presence of a nef expression cassette in a neomycin phosphotransferase gene expression plasmid greatly reduced the number of G418-resistant colonies generated in stable transfection of RAW264 cells, and many of the colonies that were formed exhibited very slow growth. The frameshift mutant was also active in reducing colony generation. Given the absence of any effect of the frameshift mutation on nef function, its actions on macrophage growth and HIV transcription are discussed in terms of the role of the N-terminal 30 amino acids and of stable secondary structures in the mRNA.
 ...
PMID:Effects of the tat and nef gene products of human immunodeficiency virus type 1 (HIV-1) on transcription controlled by the HIV-1 long terminal repeat and on cell growth in macrophages. 823 Apr 18

A potential gene therapy strategy against human immunodeficiency virus (HIV-1) is to disrupt the intracellular transport of viral proteins. We report here the binding and transporting of HIV-1 glycoprotein gp160 to lysosomes as a result of the expression of fusion genes consisting of soluble CD4 and lysosome targeting domains. The effective lysosome targeting domain tested includes a lysosomal protease zymogen, procathepsin D, and the COOH-terminal domains of three lysosome membrane proteins: lamp-1, lamp-2, and lysosomal acid phosphatase. We demonstrated that cell fusion (syncytium), caused by the transport of gp160 to the surface of HeLa-CD4+ cells, was completely abolished by the expression of these fusion genes. The lysosomal localization of gp160 in HeLa cells coexpressing CD4-fusion genes was also established. From pulse-chase experiments, we observed that gp160 and the fusion proteins were degraded, as expected of lysosomal activities. Additionally, T lymphoblastoid cells transiently and permanently expressing these fusion genes strongly retarded the propagation of human immunodeficiency virus type 1. Thus, these fusion genes can deprive HIV of newly synthesized envelope protein gp160 for the assembly of new virions and are potentially useful in gene therapy against AIDS.
 ...
PMID:Intracellular diversion of glycoprotein GP160 of human immunodeficiency virus to lysosomes as a strategy of AIDS gene therapy. 837 Apr 78

We have shown that normal C57BL/6J mice are moderately resistant to infection with murine cytomegalovirus (MCMV) and that this resistance is impaired by prior infection with LP-BM5 MuLV, which causes a disease (MAIDS) similar to early HIV-induced disease. This study investigates macrophage function in MAIDS+ mice challenged with MCMV. MAIDS reduces the influx of cells into the peritoneal cavity seen in normal C57BL/6J mice 6 days after MCMV infection. The infiltrates contained cells that resembled activated macrophages, as they took up colloidal gold, expressed the macrophage marker Mac-1, had high levels of acid phosphatase activity, and were lymphocytostatic when co-cultured with activated T cells. MAIDS+ mice had a higher percentage of cells able to take up colloidal gold and higher acid phosphatase activity per cell. The cells were also more lymphocytostatic and produced higher levels of interleukin-1 and tumor necrosis factor-alpha on days 4 and 6 after MCMV infection. Hence, MAIDS enhances baseline and induced macrophage activity, but depresses infiltration into the site of inflammation.
 ...
PMID:The inflammatory macrophage response to MCMV in mice with a retroviral immunodeficiency syndrome (MAIDS). 869 22

3 female condoms, or "vaginal pouches" as they are called by the FDA (US Food and Drug Administration) are expected to be marketed in the US in 1991, the Bikini Condom from International Prophylactics Inc., Princeton NJ; Women's Choice from M.D. Personal Products, Hayward CA; and Reality from Wisconsin Pharmacal Co., Jackson, WI. The advantages of the female condoms are control for women over contraception and sexually transmitted diseases (STDs), availability over the counter, no need for spermicides, thicker than male condoms with better barrier effectiveness and less breakage and slippage, and reported heightened sensation for women. The disadvantages are difficulty for inexperienced women to insert, unappealing appearance of part of device protruding from vagina, interference with foreplay, cost of $1.50-$2.40 each, few reports of vaginal irritation. The Bikini Condom looks like a G-string panty with a condom pouch that is automatically introduced into the vagina with coitus. Bikini had a breakage rate of 0.5%, compared to 1-2% for male condoms, an acceptance level of 56%, and can be used 5-10 times. It effectively blocked STDs and HIV (human immunodeficiency virus). Women's Choice has a 2-inch diameter flexible ring that covers the introitus, and a thickened dome of latex resembling a diaphragm at the deep end, lubricated with silicone. 20% of women reported increased clitoral and labial sensation during use. It prevented transfer of semen acid phosphatase, and enzyme smaller than STDs and viruses. Reality condom is a polyurethane sheath with an inner ring similar to a diaphragm, but fitting more loosely, and an outer ring covering part of the vulva, all inserted with an applicator. It had a leakage rate of 0.6% compared to 3.5% for male condoms, and a slippage rate of 2.7% compared to 8.1% slippage and breakage of male condoms. 5% of users reported vaginal irritation. 65% of women and 80% of men liked Reality. Generally people in female condom trials either strongly liked or disliked them. They are so novel that they appeal to people with an "open mind," and to those with experience with condoms and other barrier methods.
 ...
PMID:Female condoms scheduled to reach U.S. market this year. 1231 52

A 53-year-old, male patient presented with pain in the middle area of the back of his left foot. The painful area was associated with a reddish dome-shaped swelling of 24 by 18 mm which had ulcerated in the center part. Histopathologically, the cutaneous lesion consisted of an ulcer surrounded by abscess and granuloma and numerous acid-fast organisms were observed. Subsequently, the area just below the left inguinal area developed redness and swelling approaching the size of a quail egg. The patient responded favorably with rifampicin, levofloxacin, and minocycline therapy. The patient was immunodeficient, but negative for HIV-1 and HIV-2 antibodies and the etiology of his immunodeficient state is unclear. Skin tissues or pus were cultured at 37 degrees C on 2% Ogawa and BBL MGIT. Acid-fast organisms were recovered on MGIT within 4 to 12 days, while 2% Ogawa medium failed to recover acid-fast bacteria. Using growth from the positive MGIT tube as inoculum, MycoBroth, 7H9 broth, 7H11.2% Ogawa supplemented with or without iron complexes, and blood agar were inoculated and cultured at 30 and 37 degrees C. Growth at 30 and 37 degrees C was seen with MycoBroth, 7H9, hemin (60 microM) or ferric ammonium citrate (15 mg/ml) supplemented 7H11 and blood agar as well as 7H11 supplemented with factor X. Growth at 30 degrees C only was observed for ferric ammonium citrate supplemented 7H9 and 2% Ogawa. Generally, growth at 30 degrees C was better than that at 37 degrees C in all media. No growth at either temperature was observed with hemin or factor X supplemented 2% Ogawa. With respect to the biochemical characterization, the isolate was negative for niacin, nitrate reduction, urease, arylsulfatase, Tween 80 hydrolysis, catalase, 68 degrees C catalase, acid phosphatase, and tellurite reduction, while strongly positive for neutral red test. Sequencing of the 16S rRNA gene showed the isolate to be consistent with Mycobacterium haemophilum. Based on the composite characterization, the isolate was identified as M. haemophilum. This is the second case report of M. haemophilum infection in Japan in the literature.
 ...
PMID:[Bacteriological features of Mycobacterium haemophilum isolated from skin lesions in an immunodeficient patient]. 1521 60

The present study was undertaken to examine the state of intracellular components and leukocytes and the role of the lipid peroxidation (LPO) system and antioxidative defense (AOD) in the pathogenesis of HIV infection. The parameters of the enzymatic link of the antioxidative system and LPO processes and leukocytic intracellular components in 108 patients with HIV infection are presented. In the HIV-infected patients, the state of intracellular components of leukocytes showed a heterodirectional pattern. Thus, the values of myeloperoxidase and cationic protein exhibited a regular trend for a decrease with the maximum inhibition when secondary diseases occurred. The activity of acid phosphatase, glycogen and spontaneous HCT test increased with progression of the disease. The findings suggest that there are severe LPO disorders, as documented by a significant increase in its products forming at different stages of the peroxide cascade of hydroperoxides: malonic dialdehyde and dienic conjugates. The rate of LPO-AOD processes depends on the stage of the disease and the treatment performed. It is important to note that in HIV-infected patients the increased rate of LPO was followed by the considerably suppressed overall antioxidative activity of blood, catalase, and superoxide dismutase. The decrease in these parameters suggests a severe disturbance of the antioxidative system in different periods of the disease. The enhanced LPO activity in patients with HIV infection is likely to be one of the pathogenetic links of development of the disease and requires corrective therapy.
 ...
PMID:[Leukocytic intracellular components and proantioxidative systems in HIV-infected patients]. 1835 22

None of the clinical trials of anti-HIV gels based on conventional polymers or lipid emulsions has been successful, suggesting the need of new molecular design of the anti-HIV gels. This paper reports the conversion of anti-HIV prodrugs into self-delivery supramolecular hydrogels. By covalently conjugating reverse transcriptase inhibitors to a versatile self-assembly motif, the hydrogelators that self-assemble to form supramolecular nanofibers as the matrices of hydrogels in a weak acidic condition are obtained. Upon the treatment of prostate acid phosphatase (PAP), the hydrogels exhibit drastically enhanced elasticity. The hydrogelators are biocompatible and able to release the inhibitors under physiological condition. The use of the self-assembly motif as a self-delivery agent containing non-steroid anti-inflammatory drug (NSAID) renders this hydrogel to be both anti-inflammatory and anti-HIV. This work illustrates an unprecedented approach for designing multifunctional supramolecular hydrogels that may serve as potential anti-HIV hydrogels for sustained drug release.
...
PMID:Self-delivery multifunctional anti-HIV hydrogels for sustained release. 2361 84


<< Previous 1 2